Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II/III study for its Category 1 product candidate, jacktinib tablets. The study will focus on adolescent and adult patients suffering from non-segmental vitiligo.
Jacktinib, a Janus kinase (JAK) inhibitor, is recognized for its significant inhibitory effect on JAK1, JAK2, JAK3, and TYK2, with particularly potent activity against JAK2 and TYK2. This drug is currently under investigation in multiple clinical studies for a range of immunoinflammatory and fibrotic diseases. These include myelofibrosis, severe alopecia areata, moderate to severe atopic dermatitis, ankylosing spondylitis, idiopathic pulmonary fibrosis, and moderate to severe plaque psoriasis, among others.- Flcube.com
